Safety of very low LDL-cholesterol: Ten common concerns, misconceptions, and evidence-based clarifications - PubMed
3 hours ago
- #LDL-cholesterol safety
- #lipid-lowering therapy
- #cardiovascular risk
- Safety of very low LDL-cholesterol (LDL-C) levels is supported by evidence, especially for high-risk patients, with no consistent increase in cognitive impairment, cancer, cataracts, hemorrhagic stroke, or hormonal dysfunction.
- Two key safety considerations with intensive LDL-C lowering are statin-associated dysglycemia/new-onset diabetes and muscle-related symptoms, but their absolute risks are modest and outweighed by cardiovascular benefits.
- PCSK9-targeted therapies show no clinically meaningful excess diabetes or muscle toxicity at ultra-low LDL-C levels, despite genetic signals suggesting potential metabolic effects.
- Clear LDL-C definitions, transparent communication of risks and benefits, and shared decision-making are essential to counter misinformation and improve adherence to lipid management guidelines.